Shafique Virani - Sep 15, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Business Officer
Signature
/s/ Nathan Hatfield, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Sep 15, 2022
Transactions value $
-$122,535
Form type
4
Date filed
9/16/2022, 06:58 PM
Previous filing
Aug 17, 2022
Next filing
Oct 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $11.1K +5K +5.06% $2.22* 104K Sep 15, 2022 Direct F1
transaction RXRX Class A Common Stock Sale -$128K -9.6K -9.25% $13.34 94.2K Sep 15, 2022 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$5.59K -400 -0.42% $13.97 93.8K Sep 15, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -5K -0.76% $0.00 657K Sep 15, 2022 Class A Common Stock 5K $2.22 Direct F1, F4
holding RXRX Stock Option (Right to Buy) 80.5K Sep 15, 2022 Class A Common Stock 0 $11.40 Direct F5
holding RXRX Stock Option (Right to Buy) 5.44K Sep 15, 2022 Class A Common Stock 0 $11.40 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.89 to $13.82 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.93 to $14.07 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4 One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. 704,955 shares were originally subject to this stock option upon the grant date.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.